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Background: A deleterious, late-onset side effect of thoracic radiotherapy is
the development of radiation-induced heart disease (RIHD). It covers a spectrum
of cardiac pathology including also heart failure with preserved ejection fraction
(HFpEF) characterized by left ventricular hypertrophy (LVH) and diastolic dysfunction.
MicroRNA-212 (miR-212) is a crucial regulator of pathologic LVH via FOXO3-mediated
pathways in pressure-overload-induced heart failure. We aimed to investigate whether
miR-212 and its selected hypertrophy-associated targets play a role in the development
of RIHD.
Methods: RIHD was induced by selective heart irradiation (50Gy) in a clinically
relevant rat model. One, three, and nineteen weeks after selective heart irradiation,
transthoracic echocardiography was performed to monitor cardiac morphology and
function. Cardiomyocyte hypertrophy and fibrosis were assessed by histology at week
19. qRT-PCR was performed to measure the gene expression changes of miR-212
and forkhead box O3 (FOXO3) in all follow-up time points. The cardiac transcript level
of other selected hypertrophy-associated targets of miR-212 including extracellular
signal-regulated kinase 2 (ERK2), myocyte enhancer factor 2a (MEF2a), AMP-activated
protein kinase, (AMPK), heat shock protein 40 (HSP40), sirtuin 1, (SIRT1), calcineurin
A-alpha and phosphatase and tensin homolog (PTEN) were also measured at week 19.
Cardiac expression of FOXO3 and phospho-FOXO3 were investigated at the protein level
by Western blot at week 19.
Results: In RIHD, diastolic dysfunction was present at every time point. Septal
hypertrophy developed at week 3 and a marked LVH with interstitial fibrosis developed at
week 19 in the irradiated hearts. In RIHD, cardiac miR-212 was overexpressed at week
3 and 19, and FOXO3 was repressed at the mRNA level only at week 19. In contrast, the
total FOXO3 protein level failed to decrease in response to heart irradiation at week 19.
Other selected hypertrophy-associated target genes failed to change at the mRNA level
in RIHD at week 19.
Sárközy et al. miR-212 in Radiation-Induced Heart Disease
Conclusions: LVH in RIHD was associated with cardiac overexpression of
miR-212. However, miR-212 seems to play a role in the development of LVH
via FOXO3-independent mechanisms in RIHD. As a central regulator of pathologic
remodeling, miR-212 might become a novel target for RIHD-induced LVH and
heart failure.
Keywords: thoracic irradiation, left ventricular hypertrophy, heart failure with preserved ejection fraction (HFpEF),
miRNA-212, FOXO3
INTRODUCTION
Radiotherapy has an important role, among other therapeutic
modalities, in the treatment of thoracic tumors including breast,
lung, esophageal and childhood cancers or Hodgkin’s lymphoma.
About half of cancer patients are treated with radiotherapy
(1). Although the application of modern radiotherapy planning
and delivery techniques significantly improves the radiation
protection of the heart, in many cases, the whole heart, or part
of it, still receives a dose sufficient enough to cause radiation-
induced heart disease (RIHD) with chronic, and often severe
consequences (1). RIHD develops many years or decades after
radiotherapy in a dose-dependent manner (2, 3). Premature
coronary heart disease, electrical conduct defects or valve
abnormalities are often associated with RIHD (4–6). In the
early phase, RIHD often presents as heart failure with preserved
ejection fraction (HFpEF), characterized by LVH and diastolic
dysfunction (1, 7, 8). Radiotherapy significantly improves cancer
patient survival; however, in the long-term, patients are at
risk of RIHD and subsequent heart failure which becomes a
major health issue affecting outcome, quality of life and health
care costs (1). Unfortunately, therapeutic options for RIHD are
currently insufficient.
Radiation deteriorates the heart structure and function by
inducing changes to the vasculature, i.e., coronary arteries and
microvessels, and directly acting on the myocardium (9). The
focus of the studies so far has been on the vascular effects, which
indirectly influence the myocardium (3, 6, 10, 11). Recently,
more data has become available on the radiation-induced direct
effect on the myocardial structure. Interstitial inflammation and
progressive fibrosis are well-known pathological effects of RIHD
(12). They have been shown to be mediated by oxidative stress,
the activation of pathologic NO-cGMP-PKG signaling, cytokine
and growth factor cascades such as IL-4, IL-13, Rho/ROCK
pathway and transforming growth factor beta (TGF-β) (1, 7,
9, 13, 14). Histopathological examination of cardiac lesions of
RIHD shows hypertrophic cardiomyocytes, inflammatory cells,
fibroblasts, and excessive deposition of collagens (1, 7, 14).
Radiation-induced hypertrophy and fibrosis of the myocardium
Abbreviations: AKT, protein kinase B; AMPK, AMP-activated protein kinase;
cGMP, cyclic guanosine monophosphate; ERK2, extracellular signal-regulated
kinase 2; FOXO3, forkhead box O3; HFpEF, heart failure with preserved
ejection fraction; Hsp, heat shock protein; IL, interleukin; LVH, left ventricular
hypertrophy; Mef, myocyte enhancer factor; miR, microRNA; NO, nitric oxide;
PKG, cGMP-dependent protein kinase; PTEN, phosphatase and tensin homolog;
RIHD, radiation-induced heart disease; ROCK, Rho-associated kinase; TAC,
transverse aortic constriction; TGF-β, transforming growth factor beta.
ultimately leads to a decrease in elasticity, ductility, and the
development of diastolic heart failure. Only a few studies exist so
far on the mechanisms of radiation-induced diffuse myocardial
injury. The initial phase of RIHD includes reactive cardiac
hypertrophy with enlarged cardiomyocytes (1, 7, 15). Very little
is known about the mechanisms of cardiac hypertrophy and the
pathological remodeling in RIHD.We have previously developed
a clinically relevant rat model of RIHD, characterized by LVH and
simultaneous interstitial fibrosis (16). Our present study is based
on this RIHD model.
Endogenous microRNAs (miRs, 22 bp) are non-coding
RNA species that are post-transcriptional regulators targeting
specific mRNAs, resulting in an increase of mRNA degradation
via complementary binding and the suppression of protein
synthesis, thus influencing cellular function (17). miRs have been
described as “master switches” in cardiovascular biology, and
the dysregulation of specific miRs are key pathological factors in
many cardiovascular diseases (18–21). The miR-212/132 cluster
is considered to be a central regulator of the development
of pressure-overload-induced LVH and heart failure via the
repression of the anti-hypertrophic transcription factor FOXO3
inmice with transverse aortic constriction (TAC) (22). Moreover,
the overexpression of miR-212 separate from miR-132, was
reported to play a role in the development of LVH and heart
failure via fetal gene reprogramming in human hearts (23).
Furthermore, the pro-hypertrophic potential of miR-212 was
also confirmed in primary neonatal rat cardiomyocytes (24).
Beyond FOXO3, other predicted or validated LVH-associated
direct targets of miR-212 have been identified. They include e.g.,
the extracellular signal-regulated kinase 2 (ERK2) (25), myocyte
enhancer factor 2a (MEF2a) (26); AMP-activated protein kinase
(AMPK) (27); heat shock protein 40 (HSP40) (28); sirtuin 1
(SIRT1) (29); calcineurin A-alpha (30); and phosphatase and
tensin homolog (PTEN) (31).
So far there is no literature available on cardiac miR-212
and its targets in the development of RIHD. Therefore, we
aimed to investigate the potential role of miR-212 and its
selected hypertrophy-associated targets in the development of
LVH during the early phases of RIHD.
MATERIALS AND METHODS
The datasets generated for this study are available on request
from the corresponding author. This study was carried out in
accordance with the recommendations of the National Institutes
of Health Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85-23, Revised 1996). The protocol was
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approved by the Animal Research Ethics Committee of Csongrád
County (XV.1181/2013) and the University of Szeged. All
institutional and national guidelines for the care and use of
laboratory animals were followed.
Animals
A total of 48 male Sprague-Dawley rats (200–220 g, 6–7 weeks
old) were used (n = 8 in each group) in three separate
experiments. After 1 week of acclimatization in a temperature-
controlled room (22 ± 2◦C; relative humidity 55 ± 10%), the
animals were randomly assigned to different groups. A total of 24
animals received selective heart irradiation to induce RIHD, and a
total of 24 animals served as controls. The animals were housed in
pairs in individually ventilated cages (Sealsafe IVC system, Italy)
in a temperature-controlled room with a 12 h:12 h light/dark
cycle. Standard rat chow supplemented with 5% fat (Innovo Kft.,
Gödöllo˝, Hungary) and tap water were supplied ad libitum (16).
Experimental Setup
Animals were divided into three control and three irradiated
groups in separate experiments (n = 8 in each group)
(Figure 1). In the irradiated groups, animals received a single
dose of 50Gy delivered to the whole heart to induce RIHD.
Groups were followed-up for 1, 3, and 19 weeks, respectively.
Cardiac morphology and function were assessed by transthoracic
echocardiography in all time points. The development of LVH
and fibrosis in chronic RIHD was verified by the measurement
of myocardial fiber diameters as well as picrosirius red staining
for collagen at week 19. Total RNA was isolated from the
hearts, and the myocardial expression of miR-212 and its direct
target FOXO3 were measured by qRT-PCR in every time point.
Myocardial expression of selected mRNA targets beyond FOXO3
was also measured by qRT-PCR at week 19. Moreover, cardiac
expression of total-FOXO3, phospho-FOXO3, total-AKT, and
phospho-AKT were measured using Western blot technique
at week 19.
Heart Irradiation
Heart irradiation with a single dose of 50Gy was carried out as
described previously (16). Briefly, the planning of the irradiation
was based on a 3Dmodel (Figure 1A), and the dose was delivered
to the geometric center of the heart. For better coverage of the
heart and lung protection, a 6 MeV electron radiation was given
with a circle-shaped aperture with a 2 cm diameter (Figure 1B).
The radiation dose was delivered with a Primus linear accelerator
(Siemens Healthcare GmbH, Erlangen, Germany) at a dose
intensity of 5 Gy/min if the appropriate position of the animal
was proven using a built-in electronic portal imaging device
(Figure 1C). Before the irradiation, rats were anesthetized with
sodium pentobarbital (Euthasol, ip. 40 mg/kg, Produlab Pharma
b.v., Raamsdonksveer, The Netherlands), then fixed in the supine
position to a flat surface couch.
Transthoracic Echocardiography
Cardiac morphology and function were assessed by transthoracic
echocardiography at week 1, 3, and 19 to monitor the
development of RIHD (Figure 1D). Rats were anesthetized with
2% isoflurane (Forane, AESICA, Queenborough Limited Kent,
UK). Then, the chest was shaved, and the rat was placed in a
supine position onto a heating pad. Two-dimensional, M-mode,
Doppler, and tissue Doppler echocardiographic examinations
were performed in accordance with the criteria of the American
Society of Echocardiography with a Vivid 7 Dimension
ultrasound system (General Electric Medical Systems) using a
phased array 5.5–12 MHz transducer (10S probe) as described
previously (16, 32, 33). Data of three consecutive heart cycles
were analyzed (EchoPac Dimension software; General Electric
Medical Systems) by an experienced investigator in a blinded
manner. The mean values of three measurements were calculated
and used for statistical evaluation.
Ex vivo Cardiac Perfusions and Tissue
Harvesting
The hearts were weighed after 5 min of ex vivo heart perfusion
(34–36). Apical and basal parts of the heart were freshly frozen
and used for biochemical measurements in every follow-up time
point (Figure 1D). A cross-section of the whole heart at the
ring of the papillae was cut and fixed in 4% buffered formalin
for histological analysis at week 19 (Figure 1D). Following the
removal of the heart, the presence of pleural fluid was checked
and collected from the chest. Body and lung weights were also
measured in every follow-up time point.
Hematoxylin-Eosin Staining
Five-micrometer paraffin-embedded transverse cut sections of
the formalin-fixed subvalvular area of the ventricles were stained
with hematoxylin-eosin, in the samples collected at week 19.
On these slides, myocardial fiber diameters were measured to
verify the development of LVH as described previously (37,
38). Transverse transnuclear widths (cardiomyocyte diameter)
were measured of 100 longitudinally oriented, mono-nucleated
cardiomyocytes on left ventricle sections cut on the same
plane (37, 38).
Picrosirius Red Staining and Image
Analysis
Five-micrometer paraffin-embedded transverse cut sections of
the formalin-fixed subvalvular area of the ventricles were stained
with picrosirius red staining in the samples collected at week 19,
to assess cardiac fibrosis as described previously [Figure 1D; (16,
38)]. Histological slides were scanned with a Pannoramic P250
scanner (3D-Histech, Budapest, Hungary) and digital images at
the magnification of ×40 and ×100 were captured. Medium-
size vessels and their perivascular connective tissue sheet, the
subepicardial and subendocardial areas were avoided as best as
possible. The picrosirius red dyed images were analyzed with an
in-house developed program as described previously (16, 38).
This program determines the proportion of red pixels of heart
sections using two simple color filters. For each Red-Green-Blue
(RGB) pixel, the program calculates the color of the pixel in Hue-
Saturation-Luminance (HSL) color space. The first filter is used
for detecting red portions of the image. The second filter excludes
any white (empty) or light gray (residual dirt on the slide) pixel
from further processing using a simple RGB threshold. In this
Frontiers in Oncology | www.frontiersin.org 3 July 2019 | Volume 9 | Article 598
Sárközy et al. miR-212 in Radiation-Induced Heart Disease
FIGURE 1 | Experimental protocol figure. (A) 3D visualization of the rat heart based on CT scans, (B) positioning of the rat for delivering the radiation dose with a
Primus linear accelerator under sodium pentobarbital anesthesia, (C) appropriate position of the animal proven by portal imaging, (D) experimental protocol.
way, the program groups each pixel into one of two sets: pixels
considered red and pixels considered green but neither red,
nor white, nor gray. Red pixels in the first set correspond to
connective tissue and fibrosis. Green pixels in the second set
correspond to cardiac muscle. Dividing the number of elements
in the first set by the number of elements in both sets gives the
proportion of the connective tissue compartment of the heart
area examined.
MicroRNA Expression Profiling
by qRT-PCR
Quantitative RT-PCR was performed with miR-specific primers
to monitor miR expression as described earlier [Figure 1D;
(22, 38)]. In the case of miR-212, RNA was isolated using
Trizol reagent (Invitrogen, #15596-018) from heart tissue. For
quantitative detection of miR-212, TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, #4366597), TaqMan
miR-212, and snoRNA (U64702) Assays (Applied Biosystems,
#A25576 and #4427975), and Absolute Blue qPCR Mix
(Abgene, #AB-4136/B) were used according to themanufacturer’s
instructions. SnoRNA was used as a control for normalization.
mRNA Expression Profiling by qRT-PCR
Target mRNAs of miR-212 associated with cardiac hypertrophy
and heart failure were selected in the TargetScan database.
Quantitative RT-PCR was performed with gene-specific
primers to monitor mRNA expression as described previously
[Figure 1D; Table 1; (38, 39)]. RNA was isolated using Qiagen
RNeasy Fibrous Tissue Mini Kit (Qiagen, #74704) from heart
tissue. Briefly, 3 µg of total RNA was reverse transcribed using
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, #4368814), specific primers and FastStart Essential
DNA Green Master (Roche, #06402712001) were used according
to the manufacturer’s instructions. Peptidyl prolyl isomerase
A (Ppia), hypoxanthine phosphoribosyltransferase 1 (Hprt1),
ribosomal protein lateral stalk subunit P2 (Rplp2), and
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) were used
as controls for normalization (Table 1).
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TABLE 1 | Primer sequences.
Gene name Gene symbol Forward primer sequence Reverse primer sequence
Peptidylprolyl isomerase A (cyclophilin A) Ppia tgctggaccaaacacaaatg caccttcccaaagaccacat
Hypoxanthine phosphoribosyltransferase 1 Hprt1 gaccggttctgtcatgtcg acctggttcatcatcactaatcac
Ribosomal protein lateral stalk subunit P2 Rplp2 agcgccaaagacatcaagaa tcagctcactgatgaccttgtt
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Gapdh gaagggctcatgaccacagt ggatgcagggatgatgttct
Natriuretic peptide A (ANP) Nppa cacagatctgatggatttcaaga cctcatcttctaccggcatc
Natriuretic peptide B (BNP) Nppb gtcagtcgcttgggctgt ccagagctggggaaagaag
Myosin heavy polypeptide 6, cardiac muscle, alpha (α-MHC) Myh6 cgaaactgaaaacggcaag catagcgctccttgagattgt
Myosin heavy polypeptide 7, cardiac muscle, beta (β-MHC) Myh7 atccctggatcaggacaaga agcttcaggtcaccctcca
Protein phosphatase 3 catalytic subunit alpha Ppp3ca tgaggctgaaaaagcaatacg aaaccctttgcctcttcaaaa
Protein phosphatase 3 catalytic subunit beta Ppp3cb tcagaagaagatggatttgacg tgctcggatcttgttcctg
Nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 4
Nfatc4 gggggctgtcaaggctgctc gcgcccgatgtctgtctcacc
Muscle atrophy F-box protein (atrogin 1) Fbx32 ccatcaggagaagtggatctatgtt gttcatgaagttcttttgggcgatgc
Myocyte-enriched calcineurin-interacting protein 1 (MCIP1.4) Rcan1 agctccctgattgcctgtgt tttggccctggtctcacttt
Forkhead box O3 Foxo3 gctaagcaggcctcatctca ttcggtcagtttgagggtct
Mitogen activated protein kinase 1 (ERK2) Mapk1 tctgcaccgtgacctcaa gcaaggccaaagtcacaga
Myocyte enhancer factor 2a Mef2a gcacacagagcaccttgtaga ttaggagacaagtagtccaaggaag
Protein kinase AMP-activated catalytic subunit alpha 2
(AMPK)
Prkaa2 gacaatcggagctatcttctagactt aggtgttgaagaaccagacctc
DnaJ heat shock protein family (Hsp40) member A2 Dnaja2 aggtgtgcgcattatgataaga cggtctttttcattgatgacct
Sirtuin 1, transcript variant X1 (predicted) Sirt1 ttcgtggagatatttttaatcaggt ctggtaagttttcaccaaagaagac
Phosphatase and tensin homolog Pten catgagcgagttggtcaaga ccatgctgtgctggttca
Collagen type III alpha 1 Col3a1 gaggaatgggtggctatcct ggtatccaggagaaccaggag
Collagen type I alpha 1 Col1a1 gggtctagacatgttcagctttg ggcagtggcccctaagag
Matrix Metalloprotease 2 (MMP-2)
Zymography
Cardiac MMP-2 activity was measured at week 19 from
homogenized samples, to estimate the collagen breakdown
in the cardiac extracellular matrix as we described previously
(40, 41). Briefly, polyacrylamide gels were copolymerized with
gelatin, and a 40 µg protein was separated by electrophoresis
(150V, 1.5 h) in each lane. Following electrophoresis, gels
were washed with 2.5% Triton X-100 and incubated for 20 h
at 37◦C in incubation buffer. Gels were then stained with
0.05% Coomassie Brilliant Blue in a mixture of methanol/acetic
acid/water and de-stained in aqueous 4% methanol/8% acetic
acid. Zymograms were digitally scanned, and band intensities
were quantified using Quantity One software (Bio-Rad,
Hercules, CA) (41).
Western Blot
To investigate gene expression changes at protein quantity
and activity level, standard Western blot technique was used
in case of phospho-AKT, AKT, phospho-FOXO3, and FOXO3
with GAPDH loading background at week 19 [Figure 1D; (38,
42, 43)]. Heart tissue samples (n = 7–8) were homogenized
with an ultrasonicator (UP100H Hielscher, Teltow, Germany)
in RIPA (Radioimmunoassay) buffer (50mM Tris–HCl (pH
8.0), 150mM NaCl, 0.5% sodium deoxycholate, 5mM EDTA,
0.1% SDS, 1% NP-40 (Cell Signaling, Carlsbad, CA, USA)
supplemented with protease inhibitor cocktail and phosphatase
inhibitors PMSF and NaF (Sigma, Saint Louis, MO, USA).
The crude homogenates were centrifuged at 15,000 × g for
30min at4◦C. After quantification of protein concentrations
of the supernatants, using the BCA Protein Assay Kit (Pierce,
Rockford, IL, USA), 25 µg reduced and denaturated protein
was loaded and SDS-PAGE (10% gel, 90V, 2 h) was performed
followed by the transfer of proteins onto a nitrocellulose
membrane (20% methanol, 35V, 2 h). The efficacy of the
transfer was checked using Ponceau staining. The membranes
were cut horizontally into three parts corresponding to the
molecular weights of AKT, FOXO3, and GAPDH. Then the
membranes were blocked for 1 h in 5% (w/v) BSA at room
temperature and then incubated with primary antibodies (Cell
Signaling, Beverly, MA, USA; overnight, 4◦C, 5% BSA) in
the concentrations of 1:1,000 against AKT (#9272), phosho-
AKT (Ser473, #4060), phospho-FOXO3 (Ser253; #13129), 1:500
against FOXO3 (#2497) or 1:5,000 against GAPDH (#2118
overnight, 4◦C, 1% BSA). Then the membranes were incubated
with horseradish peroxidase (HRP)-conjugated goat anti-rabbit
secondary antibody 1:2,000 (1:1,000 for FOXO3, 1:5,000 for
GAPDH) (Dako Corporation, Santa Barbara, CA, USA; 45min,
room temperature, 1% BSA). After assessment of phosphorylated
proteins, the membranes were stripped and reassessed for the
total amount of proteins. An enhanced chemiluminescence kit
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(Cell Signaling, Carlsbad, CA, USA) was used to develop the
membranes. The chemiluminescence signals were analyzed and
evaluated by Quantity One Software. Signals of GAPDH and
FOXO3, as well as AKT, develop at different time points.
Therefore, the expositions times are different for GAPDH,
FOXO3, and AKT. For signal evaluation of Western blots,
we always used the non-oversaturated films for correct signal
detection (Supplementary Figures).
Statistical Analysis
Statistical analysis was performed using Sigmaplot 12.0 for
Windows (Systat Software Inc.). All values are presented as
mean ± SEM except the gene expression data measured by
qRT-PCR. Data showed normal distribution unless otherwise
indicated. Data measured at different follow-up time points in
separate experiments including body weight, heart weight, heart
weight to body weight ratio, lung weight and echocardiographic
parameters were compared using One-Way ANOVA between
the groups. A Bonferroni test was used as a post-hoc test. A
two sample t-test (in case of the normal distribution of the
data) or Mann Whitney U-test (in case of the non-normal
distribution of the data) was used to determine the effect of
RIHD on all measured parameters within each time point.
P < 0.05 was accepted as a statistically significant difference. In
the case of target genes, the analysis of relative gene expression
data was performed using the 2−11Ct method. Gene expression
ratios with a p < 0.05 and fold change of <−2.00 or fold
change of>2.00 were considered as repression or overexpression
respectively in gene activity.
RESULTS
Characteristics of the RIHD Models
At week 1, there was no difference in the body weight between
the control and irradiated groups (Table 2). At week 3, the
irradiated animals presented a trend toward a lower body weight
as compared to the time-matched controls (Table 2). At week
19, the irradiated rats showed significantly lower body weight
as compared to the time-matched controls (Table 2). At autopsy
at week 1 and 3, there was no pleural fluid in the irradiated
animals. At week 19, the presence of extensive pleural fluids was
found in almost all animals in the irradiated group (data not
shown). At the macroscopic level, no major heart pathologies
(including the large vessels, the valves, the coronary arteries,
etc.) were observed in the irradiated groups at any follow-up
time point. At week 1 and 3, lung weights were significantly
increased in the irradiated groups as compared to the time-
matched controls (Table 2). A higher lung weight might suggest
the presence of acute inflammation and lung edema due to the
acute deteriorating effects of ionizing radiation. At week 19,
no difference was found in lung weights between the groups
(Table 2). At week 1 and 3, there was no difference in heart
weights between the irradiated groups and their time-matched
controls (Table 2). However, the heart to body weight ratio
showed a trend toward an increase in the irradiated group at
week 3 (Table 2). The increased heart to body weight ratio might
suggest the development of starting cardiac hypertrophy. At week
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19, the tibia length (4.23± 0.05 vs. 4.46± 0.04 cm, p= 0.003) and
the heart weight was significantly lower in the irradiated group
than in the control group pointing out the growth retardation
in these animals (Table 2). At week 19, no sign of radiation-
induced pneumonitis or lung fibrosis was visible, confirming the
appropriateness of our models for the study of the acute and
chronic effects of selective heart irradiation. At week 19, all of
the morphometric parameters (body weight, heart weight, heart
weight to body weight ratio, and lung weight) were significantly
higher in both the control and irradiated groups as compared to
week 1 parameters within the same group, due to the growth of
the animals (Table 2).
HFpEF Developed in RIHD at Week 19
Transthoracic echocardiography was performed at week 1, 3,
and 19 in separate experiments to investigate whether the
development of acute and chronic RIHD leads to an alteration in
myocardial morphology and function (Table 3; Figures 1A, 2).
At week 1, the left ventricular wall thicknesses were not
different between the irradiated and time-matched control
groups (Table 3). In contrast, the left ventricular end-systolic and
end-diastolic diameters, as well as the volumes, were significantly
decreased in the irradiated animals, proving an acute dysfunction
in the contraction and relaxation as well (Table 3). Stroke volume
showed a statistically non-significant trend toward a decrease
in the irradiated animals as compared to the time-matched
controls (Table 3). There was a trend toward an increase in
heart rate in the irradiated animals, likely a compensatory
mechanism, to maintain cardiac output (Table 3). The ratio
of the early flow velocity E and the septal mitral annulus
velocity e′ significantly increased, and e′ significantly decreased
in irradiated rats indicating the presence of concomitant diastolic
dysfunction (Table 3).
At week 3, septal wall-thicknesses both in diastole and systole
were significantly increased in the irradiated rats indicating the
development of LVH (Table 3). The left ventricular end-systolic
diameter was significantly decreased, and fractional shortening
was significantly increased in the irradiated animals in this early
phase of hypertrophy (Table 3). Diastolic dysfunction was also
present in the irradiated group characterized by significantly
increased E/e′ and significantly decreased e′ (Table 3).
At week 19, left ventricular wall thicknesses including anterior
and inferior walls both in systole and diastole, as well as septal and
posterior walls in diastole, significantly increased in irradiated
rats pointing to the presence of a marked concentric LVH
(Table 3; Figures 2A–C). In addition, both left ventricular end-
systolic and end-diastolic diameters significantly decreased in
irradiated animals as compared to the controls (Figure 2D).
Indeed, left ventricular end-systolic, as well as end-diastolic
volumes also decreased in irradiated rats (Table 3). In contrast,
ejection fraction remained unchanged in irradiated rats showing
a characteristic picture of HFpEF (Figure 2E). There was no
difference in heart rate between the two groups at this stage
(Table 3). Stroke volume and cardiac output were significantly
reduced in irradiated rats as compared to controls (Table 3;
Figure 2F). More importantly, e
′
was significantly decreased and
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FIGURE 2 | Echocardiographic results at week 19. (A) Representative M-mode images, (B) anterior and inferior wall thicknesses in systole (AWTs and IWTs),
(C) anterior and inferior wall thicknesses in diastole (AWTd and IWTd), (D) left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter
(LVEDD), (E) ejection fraction, (F) cardiac output, and (G) E/e’ ratio. White bars represent control group and black bars represent the irradiated group. RT means
radiotherapy. Values are means ± SEM, n = 8, *p < 0.05.
E/e′ was significantly increased indicating diastolic dysfunction
(Table 3; Figure 2G).
Septal and posterior wall thicknesses were significantly
increased both in the control and irradiated group at week
19 as compared to data measured at week 1 in the same
group, due to the growth of the animals (Table 3). Interestingly,
left ventricular end-diastolic and end-systolic diameters were
significantly decreased in the RIHD group at week 19 as
compared to week 1 values, indicating the presence of marked
concentric hypertrophy (Table 3). In the control group, left
ventricular end-diastolic diameter was significantly increased at
week 19 as compared to week 1 values, due to the normal growth
of the animals (Table 3). Heart rate was significantly decreased in
both the control and irradiated groups at week 19 as compared
to week 1 values which might be caused by the aging of the
animals (Table 3).
Cardiomyocyte Hypertrophy and Interstitial
Fibrosis in RIHD at Week 19
To verify the development of severe LVH seen on
echocardiographic images at week 19, cardiomyocyte
diameters were measured histologically (Figures 3A,B).
Cross-sectional cardiomyocyte diameters significantly increased
in RIHD proving the presence of LVH at the cellular level at
week 19 (Figure 3B).
Collagen deposition was assessed to investigate the
development of fibrosis in response to selective heart irradiation
at week 19 (Figures 3C,D). Significant interstitial fibrosis was
found with slight but consistent collagen depositions in all
studied segments of the irradiated hearts (Figures 3C,D). MMP2
activity also showed a decreasing trend at week 19 (Figure 3E),
suggesting that the balance between collagen breakdown and
deposition might be shifted toward deposition.
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FIGURE 3 | Histology and zymography results at week 19. (A) Hematoxylin-eosin stained slides, (B) cardiomyocyte diameter, (C) picrosirius red and fast green
stained slides, (D) cardiac collagen content, and (E) MMP2 activity. White bars represent control group and black bars represent the irradiated group. RT means
radiotherapy. Values are means ± SEM, n = 8, *p < 0.05.
Molecular Markers of Cardiac Hypertrophy
and Fibrosis
The expression of cardiac hypertrophy (alpha-MHC and beta-
MHC), fibrosis (collagen type I alpha 1 - Col1a1 - and collagen
type III alpha 1- Col3a1 -) and heart failure (A-type natriuretic
peptide [ANP] and B-type natriuretic peptide [BNP]) markers
were measured by qRT-PCR at week 1, 3, and 19 (Tables 4, 5).
At week 1 and 3, the cardiac expression of these markers showed
no difference among the irradiated and time-matched control
groups (Table 4).
At week 19, the beta-MHC to alpha-MHC ratio showed a 2.7-
fold increase among cardiac hypertrophy markers. The cardiac
expression of alpha-MHC significantly decreased in RIHD as
compared to the controls (Table 5). However, the cardiac beta-
MHC mRNA level did not change in RIHD as compared to
controls. The cardiac expression of pro-hypertrophic protein
phosphatase 3, catalytic subunit alpha and beta (i.e., calcineurin
A-alpha and calcineurin A-beta), myocyte enhancer factor 2D
(Mef2d), andmyocyte enhancer factor 2C (Mef2c) did not change
in response to selective heart irradiation as compared to the
controls (Table 5). The anti-hypertrophic atrogin-1 and the pro-
hypertrophic calcineurin pathway element myocyte-enriched
calcineurin-interacting protein 1.4 (MCIP 1.4) did not change
significantly in RIHD as compared to the controls (Table 5).
Among fibrosis and remodeling markers, the more elastic Col3a1
showed significant down-regulation in RIHD; however, the more
rigid Col1a1 failed to change in RIHD (Table 5). Consistently,
the ratio of Col1a1 to Col3a1 increased, which is a characteristic
change in left ventricular fibrosis and remodeling (44–46).
Moreover, the mRNA levels of the heart failure markers, ANP
and BNP, significantly increased in RIHD as compared to the
controls (Table 5).
Cardiac Overexpression of miR-212 at
Week 3 and 19
At week 1, there was no change in the cardiac expression
of miR-212 between the irradiated and control groups
(Table 5). Both at week 3 and 19, miR-212 was significantly
overexpressed in the irradiated hearts as compared to the
controls (Table 4; Figure 4A).
Repression of the Anti-hypertrophic
FOXO3 at the mRNA Level in RIHD Only at
Week 19
Both at week 1 and 3, there was no change in the cardiac
expression of the anti-hypertrophic miR-212 target molecule
FOXO3 between the irradiated and time-matched control
groups (Table 4). In contrast, cardiac expression of FOXO3 was
significantly decreased at the mRNA level in irradiated hearts as
compared to controls at week 19 (Table 5; Figure 4E).
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TABLE 4 | Cardiac gene expression changes 1 and 3 weeks after the selective heart irradiation (qRT-PCR results).
Gene name Gene symbol Week 1 Week 3
Log2
change
SD log2
change
p-value Fold
change
Log2
change
SD log2
change
p-value Fold
change
miR-212 miR-212 −0.38 0.63 0.183 −1.30 1.11 0.38 0.000 2.15*
Forkhead box O3 Foxo3 −0.02 0.41 0.916 −1.01 −0.19 0.29 0.170 −1.14
Myosin, Heavy Polypeptide 6, Cardiac
Muscle, Alpha (α-MHC)
Myh6 −0.45 0.29 0.009 −1.37 −0.38 0.61 0.193 −1.30
Myosin, Heavy Polypeptide 7, Cardiac
Muscle, Beta (β-MHC)
Myh7 −0.13 0.23 0.237 −1.09 −0.12 0.59 0.666 −1.08
Collagen, type III, alpha 1 Col3a1 −0.52 0.61 0,079 −1.44 1.11 0.97 0.027 1.24
Collagen, type I, alpha 1 Col1a1 −0.43 0.46 0.171 −1.37 0.39 0.59 0.171 1.31
Natriuretic peptide A (ANP) Nppa 0.76 1.26 0.198 1.71 0.56 0.97 0.231 1.47
Natriuretic peptide B (BNP) Nppb −0.09 0.75 0.789 −1.08 0.55 0.76 0.132 1.46
Gene expression ratios at week 1 and 3, respectively, (radiotherapy vs. control). Fold change of < −2.00 or >2.00 (repression or overexpression respectively) and a p < 0.05 were
considered as a significant change*. n = 6, unpaired t-test or Mann-Whitney U-test.
TABLE 5 | Cardiac gene expression changes 19 weeks after the selective heart irradiation (qRT-PCR results).
Gene name Gene symbol Log2 change SD log2 change p-value Fold change
miR-212 targets Forkhead box O3 Foxo3 −1.01 1.11 0.000 −2.01*
Mitogen activated protein kinase 1 (ERK2) Mapk1 −0.47 0.34 0.000 −1.39
Myocyte enhancer factor 2a Mef2a −0.10 0.52 0.051 1.10
Protein kinase AMP-activated catalytic subunit alpha 2 (AMPK) Prkaa2 −0.49 0.46 0.000 −1.41
DnaJ heat shock protein family (Hsp40) member A2 Dnaja2 −0.41 0.43 0.000 −1.33
Sirtuin 1. transcript variant X1 Sirt1 −0.34 0.38 0.000 −1.26
Protein phosphatase 3 catalytic subunit alpha (Calcineurin A-alpha) Ppp3ca −0.45 0.61 0.000 −1.37
Phosphatase and tensin homolog (PTEN) Pten −0.04 0.27 0.408 −1.03
Other Genes Myosin heavy polypeptide 6, cardiac muscle, alpha (α-MHC) Myh6 −2.04 1.08 0.007 −4.11*
Myosin heavy polypeptide 7 cardiac muscle, beta (β-MHC) Myh7 −0.62 0.33 0.003 −1.53
Collagen type III alpha 1 Col3a1 −1.45 0.87 0.000 −2.73*
Collagen type I alpha 1 Col1a1 0.14 0.72 0.253 1.10
Protein phosphatase 3 catalytic subunit beta (Calcineurin A-beta) Ppp3cb −0.44 0.24 0.000 −1.36
Muscle atrophy F-box protein (Atrogin-1) Fbxo32 −0.17 0.25 0.159 −1.12
Myocyte-enriched calcineurin-interacting protein 1 (MCIP1.4) Rcan1 −0.18 0.51 0.455 −1.13
Natriuretic peptide A (ANP) Nppa 3.88 1.80 0.000 14.77*
Natriuretic peptide B (BNP) Nppb 1.50 0.53 0.000 2.83*
Gene expression ratios at week 19 (radiotherapy vs. control). Fold change of <−2.00 or >2.00 (repression or overexpression. respectively) and a p < 0.05 were considered as a
significant change*. n = 6, unpaired t-test or Mann-Whitney U-test.
Phospho-FOXO3/Total FOXO3 Ratio in
RIHD at Week 19
The expression of the anti-hypertrophic miR-212 target molecule
FOXO3 was also investigated at the protein level using a
Western blot technique at week 19. Total FOXO3 protein levels
failed to decrease in the irradiated hearts as compared to the
controls (Figure 4F). The cardiac phospho-FOXO3 level and
the phospho-FOXO3/total FOXO3 ratio showed a statistically
non-significant trend toward an increase in RIHD as compared
to the control group (Figures 4G,H). An increased phospho-
FOXO3/total FOXO3 ratio is considered to be a characteristic
shift in pressure-overload-induced cardiac hypertrophy forms
(47). In our RIHD model, the statistically non-significant
trend toward an increase in the phospho-FOXO3/total FOXO3
ratio seems to be independent of the effect of miR-212 in
RIHD (Figure 5).
Decreased Cardiac phospho-AKT Level in
RIHD at Week 19
Moreover, we investigated the cardiac amount of both total
AKT and phospho-AKT proteins using Western blot.
Phospho-AKT is a positive regulator of the FOXO3 protein
phosphorylation, leading to a pro-hypertrophic shift in the
phospho-FOXO3/FOXO3 ratio in pressure-overload-induced
LVH models [Figure 5; (48)]. In our RIHD model, the cardiac
amount of total AKT did not differ between the two groups
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FIGURE 4 | qRT-PCR and Western blot results at week 19. (A) Cardiac miR-212 expression, (B) cardiac total AKT expression, (C) cardiac phospho-AKT expression,
(D) cardiac phospho-AKT/total AKT ratio, (E) cardiac FOXO3 mRNA expression, (F) cardiac total FOXO3 expression, (G) cardiac phospho-FOXO3 expression, and
(H) cardiac phospho-FOXO3/total FOXO3 ratio. White bars represent control group and black bars represent the irradiated group. RT means radiotherapy. Values are
means ± SEM, n = 7–8, *p < 0.05. In case of Western blot results, only the representative blot image was shown, and the mean was calculated.
(Figure 4B). However, the amount of phospho-AKT was
significantly decreased in the irradiated hearts as compared to
the controls (Figure 4C). The phospho-AKT/total AKT ratio
showed a statistically non-significant trend toward a decrease
in cardiac RIHD samples (Figure 4D). Hence, AKT does not
seem to play a crucial role in the regulation of FOXO3 in
RIHD (Figure 5).
Hypertrophy Associated mRNA Targets
Beyond FOXO3 in RIHD at Week 19
Several predictive miR-212 targets associated with hypertrophy
have been identified beyond FOXO3. Among those, we have also
investigated the cardiac expression of the extracellular signal-
regulated kinase 2 (ERK2), the myocyte enhancer factor 2a
(Mef2a); the protein kinase AMP-activated catalytic subunit
alpha 2 (AMPK); DnaJ heat shock protein family member
A2 (Hsp40); sirtuin 1, transcript variant X1 (Sirt1); protein
phosphatase 3 catalytic subunit alpha (calcineurin A-alpha);
phosphatase and tensin homolog (PTEN) (Table 5). These
target mRNAs failed to show significant down-regulation in
response to selective heart irradiation as compared to the control
hearts (Table 5).
DISCUSSION
We have previously described the rat model of RIHD in the
chronic phase (16). In our present study, we have characterized
the rat model of RIHD in the acute phase, 1 and 3 weeks
after selective heart irradiation. We also confirm the presence of
diastolic dysfunction in this model in every investigated phase
(49). In our present study, mild septal hypertrophy was found
3 weeks after the selective heart irradiation. Marked cardiac
morphological and functional changes were confirmed 19 weeks
after the selective heart irradiation, in the form of concentric LVH
and diastolic dysfunction, which are the hallmarks of HFpEF.
These morphological and functional changes were similar to
those reported in other studies (1, 7).
Two major components are thought to be responsible
for the development of RIHD in humans. One is the
progressive atherosclerosis of the coronary arteries due to
endothelial damage (5, 6). The other is diffuse injury and
inflammation of the myocardium caused by the loss of
capillaries and cardiomyocytes (9). These mechanisms could
lead to compensatory cardiomyocyte hypertrophy and interstitial
fibrosis in the early stages of RIHD (5, 6). The injury
of coronary arteries is difficult to test in wild-type rodent
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FIGURE 5 | Putative mechanisms in the development of left ventricular hypertrophy in RIHD.
models due to different serum lipid profiles (i.e., higher HDL-
cholesterol and lower LDL-cholesterol levels as compared to
humans) which naturally protect them from the development
of atherosclerosis (50). In our present study, the lack of
atherosclerosis makes it possible to study the direct effects
and mechanisms of diffuse myocardial injury and chronic
inflammation components. Available studies are mainly focused
on macro- and microvascular contributions in RIHD (3, 6,
10, 11). So far only a few studies investigated the molecular
mechanisms of radiation-induced diffuse myocardial injury and
compensatory hypertrophy (1, 7, 15).
In our present study, picrosirius red staining indicates an
increased interstitial accumulation of collagens in the RIHD
hearts. Generally, the increased collagen deposition could be
explained by either the stimulation of production or the reduced
turnover of the mRNAs and/or proteins of different collagen
types. In our RIHD model, we could not demonstrate increased
expressions of collagens at the mRNA level at week 19, only
a decrease in Col3a1 and no change in Col1a1 expression.
Likely, the excessive stimulation of collagen expression happens
at the mRNA level at earlier time points, and only the result
of an earlier stimulation was visible at the protein level in
our study. However, we observed a trend toward reduced
MMP-2 activity in RIHD hearts at week 19, which might
indicate a reduced turnover of collagens at the protein level.
There was no change in the cardiac gene expression of Col1a1
and Col3a1 in the early phases of RIHD. Therefore, the 1-
and 3-week follow-up times seem to be too early to detect
significant stimulation of collagen gene expression at the mRNA
level in RIHD. The key mediator of radiation-induced cardiac
fibrosis is thought to be a transforming growth factor beta
(TGF-β1) (15, 51). In our previous experiments, increased
plasma levels of TGF-β1 and growth differentiation factor
15 (GDF-15) were shown 12 weeks after the selective heart
irradiation with 50Gy (16). Another possible explanation is
that our RIHD model in week 19 is not in the phase of
severe fibrotic remodeling, which ultimately leads to systolic
heart failure with reduced ejection fraction (HFrEF). According
to our experimental data, the heart at 19 weeks following
irradiation is best characterized by hypertrophy, mild interstitial
fibrosis, and diastolic dysfunction, demonstrating characteristic
HFpEF. Another study demonstrated that the degeneration of
cardiomyocytes extended until 100 days after the irradiation
(15). In our chronic RIHD model, the mild interstitial fibrosis
might be developed as a reaction to diffuse cardiomyocyte cell
death (52). This replacement fibrosis is thought to be essential
in the adaptation to the loss of cardiac parenchyma and the
preservation of the heart structure in different heart failure
models (52). Thus, more severe fibrosis might be detectable at
a later stage (>19 weeks), followed by dilatation of the heart,
thinner walls and end-stage heart failure with reduced ejection
fraction in RIHD (15). A study with a 16-month follow-up time
reported that interstitial collagen deposition had a progressive
nature (15).
It is also interesting to note that the gene expression of type
III collagen fibers was significantly repressed, and the expression
Frontiers in Oncology | www.frontiersin.org 12 July 2019 | Volume 9 | Article 598
Sárközy et al. miR-212 in Radiation-Induced Heart Disease
of type I collagen fibers were not changed in response to selective
heart irradiation in our present study at week 19. Collagen type
III is of the thinner and more elastic fiber type, whereas collagen
type I is of the thicker and more rigid fiber type (44). The
increased ratio of Col1a1 to Col3a1 at the protein level could
be a factor in the stiffness and resistance to stretch in both in
HFpEF and HFrEF in different heart failure and hypertrophy
forms (44–46).
Unfortunately, therapeutic options for RIHD are currently
insufficient. Since interstitial fibrosis is a final major endpoint
of RIHD, our chronic model seems to be an adequate one,
in a series of future investigations with different anti-fibrotic
agents to prevent fibrosis in an early phase. Interestingly, a
recent study showed cardioprotective effects of an endogenously
released small peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) in
a rat model of RIHD. In this experimental study, Ac-SDKP
was reported to inhibit inflammation, fibrosis, and reduce
macrophage activation (53).
A number of studies demonstrated that miRs are critical
contributors to cardiovascular biology and disease development
(18–21, 54). So far, only two studies have been published,
describing that miR-1, as well as miR-15b, were repressed
and miR-21 was overexpressed in RIHD (55, 56). It has been
demonstrated that hypertrophic stimuli upregulated cardiac
expression of miR-212, which is necessary and sufficient to
drive the hypertrophic growth of cardiomyocytes (22). MiR-
212 was shown to be a key regulator of the development
of LVH and heart failure via the repression of the anti-
hypertrophic transcription factor FOXO3 and overactivation of
the calcineurin/NFAT signaling during heart failure development
(22). In our present study, LVH was accompanied by the
overexpression of miR-212 3 and 19 weeks after the selective
heart irradiation. Interestingly, the repression of FOXO3 at the
mRNA level was present in cardiac tissue samples in RIHD
only at week 19 (Figure 5). In contrast, the FOXO3 protein
level failed to decrease, and the phospho-FOXO3/total FOXO3
ratio showed a non-significant trend toward an increase in
RIHD at week 19 (Figure 5). Although, the increased phospho-
FOXO3/total FOXO3 ratio is a characteristic shift in cardiac
hypertrophy forms (47); it seems to be independent of the effect
of miR-212 in chronic RIHD. FOXO transcription factors are
also regulated by the protein kinase AKT [Figure 5; (48, 57)].
Therefore, we also measured the protein levels of both total
and phospho-AKT at week 19. The total-AKT level and the
phospho-AKT/total AKT ratio failed to change significantly in
the irradiated hearts as compared to the controls. It has also
been demonstrated in other LVH models that the repression
of the FOXO3 level could indirectly lead to the overactivity
of the hypertrophic calcineurin/NFAT pathway (57). In our
present study, cardiac mRNA levels of calcineurin A-alpha
and calcineurin A-beta showed a statistically non-significant
decrease in the irradiated hearts as compared to the controls.
These results suggest that the AKT/FOXO3 mediated pathways
might not play a crucial role in the development of LVH
in chronic RIHD. Nonetheless, the FOXO3 protein level and
its phosphorylation are also regulated by various molecules
beyond miR-212.
In our chronic RIHD model, we also investigated the
expression of selected regulatory genes that are predicted
targets of miR-212 and are associated with cardiac hypertrophy
in other LVH forms. Target mRNAs were Mef2a, AMPK,
Hsp40, sirtuin 1, calcineurin A-alpha, PTEN, and ERK2.
These target mRNAs failed to show a significant change
in RIHD as compared to the control hearts. Therefore, we
did not further investigate their cardiac expression at the
protein level.
The development of the LVH and HFpEF in RIHD
seems to be unique and very different from other forms
of cardiac hypertrophies, such as the commonly studied
pressure-overload-induced compensatory hypertrophy
and subsequent heart failure. In RIHD, compensatory
hypertrophy, cell survival, and recovery mechanisms could
be activated simultaneously in a distinct manner. These
individual pathways may converge in the same direction
toward key down-stream regulators (e.g., FOXO3) and
the ensuing opposite effects may extinct each other at the
protein level.
In this study, the focus was on the miR-212 with its selected
hypertrophy-associated target mRNAmolecules, the relative role
of other miRNAs or other miR-212 targets were not assessed in
the development of cardiac hypertrophy in RIHD.
In summary, this is the first study to report that LVH and
HFpEF are accompanied by characteristic overexpression ofmiR-
212 in the heart, both in the early and later phases of RIHD.
Our results suggest that miR-212 might play a significant role
in the development of RIHD via FOXO3/AKT independent
mechanisms, and the molecular mechanism of the development
of RIHD is distinct from other forms of hypertrophy and
pathological remodeling.
LIMITATIONS
Our results regarding altered cardiac gene expression
due to RIHD are based on selected miRNAs and mRNA
target molecules, however, measurement of the full rat
transcriptome should be performed in the future. Our study
is descriptive; therefore, future studies providing more in-
depth mechanistic insights should be carried out. Moreover,
therapeutic intervention was out of the scope of our present
exploratory study.
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